TITLE

LIGAND SUBMITS MAA FOR ONZAR IN EUROPE

PUB. DATE
February 2002
SOURCE
Worldwide Biotech;Feb2002, Vol. 14 Issue 2, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the regulatory application passed by Ligand Pharmaceuticals Inc. for anti-cancer medicine Onzar.
ACCESSION #
6395344

 

Related Articles

  • FDA Approves Ligand's Targret Capsules for Refractory CTCL.  // Biotech Business;Feb2000, Vol. 13 Issue 2, p3 

    Reports the approval of the United States Food and Drug Administration for the marketing of Targretin capsules, a treatment for cutaneous T-cell lymphoma (CTCL) developed by Ligand Pharmaceuticals Inc.

  • Ligand's Ontak shows potential in B- and T-cell non-Hodgkin's lymphoma.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p23 

    Reports that Ligand Pharmaceuticals' approved cancer drug Ontak may benefit patients with relapsed or refractory B- and T-cell non-Hodgkin's lymphoma, according to interim results from a phase II study presented at the 39th annual meeting of the American Society of Clinical Oncology. Mechanism...

  • Ligand plummets on lung cancer trial failure.  // PharmaWatch: Cancer;May 2005, Vol. 4 Issue 5, p13 

    Reports that Ligand Pharmaceutical Inc.'s shares have fallen close to 29 percent after its anticancer candidate, Targretin, failed to improve the survival rates in two pivotal phase III lung cancer trials. Purpose of the clinical study conducted; Observation of the researchers during the phase...

  • If Large Ligand Holder Sells, That'll Be O.K. Roberts, Ricardo // Mergers & Acquisitions Report;6/17/2002, Vol. 15 Issue 24, p1 

    Talks about the financial status of Ligand Pharmaceutical Inc.

  • Ligand Pharmaceuticals Inc.  // San Diego Business Journal;11/7/94, Vol. 15 Issue 45, p37 

    Features Ligand Pharmaceuticals Incorporated. Value; Performance record; Directors; Executive compensation; Significant stock ownership; Other information.

  • Save-the-Date: Ligand Hosting Promacta Panel Discussion on Nov 7.  // Biomedical Market Newsletter;11/9/2011, Vol. 21, p91 

    The article offers information on a panel discussion initiated by Ligand Pharmaceuticals Inc. to review and discuss the Promacta Phase III ENABLE 1 study results to be held in San Francisco, California on November 7, 2011.

  • Sun sets on county's regulatory Sunset Commission. Allen, Mike // San Diego Business Journal;10/20/97, Vol. 18 Issue 42, p3 

    Discusses the regulations covering the reporting of hazardous chemicals in San Diego, California, and how the Sunset Commission has resulted in the relatively low fees paid by Ligand Pharmaceuticals Incorporated. How much money Ligand used to pay under former regulations; Ligand's inventory...

  • Ligand Pharmaceuticals Cuts Loss Dramatically in 2009. Chambers, Heather // San Diego Business Journal;2/15/2010, Vol. 31 Issue 7, p5 

    The article examines the profit announced by the Ligand Pharmaceuticals Inc., in which it recorded a 72 million U.S. dollars charge related to its purchase of New Jersey-based biotech Pharmacopeia.

  • Ligand to Market FDA-Approved Pain Medicine. Webb, Marion // San Diego Business Journal;3/25/2002, Vol. 23 Issue 12, p10 

    Reports the approval of the U.S. Food and Drug Administration for the marketing of pain drug Avinza by Ligand Pharmaceuticals Inc. in San Diego, California. Estimation on the growth of opioid market size; Growth of the pharmaceutical company; Prediction of commercial acceleration.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics